Commercial

MLT-001: Two Distinct Markets

160M
Aesthetic Patients

Market #1: Aesthetic Fat Reduction, Cash-Pay

$43B Projected Market Size

  • 160M U.S. patients with limited options

  • No reimbursement risk — paid out of pocket

  • First-mover advantage

17M
Lipedema Patients
Excess fat specific to certain extremities is the hallmark of Lipedema, a disease with no standard of care and that affects 17 million US patients.
7M
Treatment-Resistant
Hypertension Patients
Excess perirenal fat drives Treatment-Resistant Hypertension in 7 million US patients.
3M
Heart Failure with Preserved Ejection Fraction Patients

Market #2: Medical Indications, Reimbursed

27 Million Patients with Unmet Needs

  • 17 million lipedema patients

  • 7 million patients with treatment-resistant hypertension

  • 3 million patients diagnosed with heart failure with preserved ejection fraction

Aesthetic PFL: A market waiting for its breakthrough

Like obesity before semaglutide, aesthetic Precision Fat Loss is massive and underserved. When semaglutide crossed the efficacy threshold, it expanded the obesity market 50–100×. Aesthetic PFL is obesity-adjacent, with a TAM 1.6× larger — and today remains essentially greenfield.

MLT-001 is that breakthrough.

A single dose reduced treated fat by 25–30% in one week in both ex vivo human tissue and small animal studies.

Conservative
$7B
Base case
$26B
US + INT’L Build
$43B
Bull case
$60B

Projected annual peak sales, aesthetic PFL. The $43B build below shows how the model gets there.
Detailed models available under CDA.

MLT-002: New Medical Knowledge Created a Major Opportunity

Excess tongue fat is a newly recognized cause of obstructive sleep apnea. Reducing tongue fat by 25% can improve sleep apnea by up to 90%. MLT-002 produces 25-30% fat reduction with a single treatment, making it a potential breakthrough therapy for this epidemic disease.

30MU.S. patients whose apnea is driven by excess tongue fat — MLT-001’s direct target
$10.3BGlobal sleep-apnea market in 2025, projected to reach $22.9B by 2034
60–70%Discontinuation rate for CPAP and mechanical devices